A Phase 2 interventional study of ACT-541468 and Placebo in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 10 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
University Hospital, Montpellier · Sites in France
Ages 60–85
Sterling McPherson · Sites in United States
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
Institut d'Investigació Biomèdica de Bellvitge · Sites in Spain
Ages 18–99
By country, each count listing its studies:
daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2016.
This study's enrollment of 58 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd.: none open now, 1 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.
Idorsia Pharmaceuticals Ltd.’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2015.
3 of the studies testing daridorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07328594Legacy Health SystemImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking | 2027-03-31 |
| NCT07555743Institut d'Investigació Biomèdica de BellvitgeEfficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | 2027-04 |
| NCT05924425University Hospital, MontpellierDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease | 2027-05-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Idorsia Pharmaceuticals Ltd.’s 11 in Sleep Initiation and Maintenance Disorders:
This tab as a report to print or save as PDF → With an account.
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
The study consists of 3 phases: a screening phase, a double-blind treatment phase consisting of 5 periods, and a safety follow-up phase. Safety is monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
Drug: ACT-541468 · Drug: Placebo
Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
Drug: ACT-541468 · Drug: Placebo
Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
Drug: ACT-541468 · Drug: Placebo
Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
Drug: ACT-541468 · Drug: Placebo
Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
Drug: ACT-541468 · Drug: Placebo
Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
Capsules for oral administration matching the ACT-541468 capsules
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
Time frame: Baseline to Day 1 and Day 2 of each treatment period
Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
Time frame: Baseline to Day 1 and Day 2 of each treatment period
Conducted at 10 centers in 2 countries (USA and Germany)
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 12 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 (D4, D2, D3, D1 and P) | Sequence 2 (D2, P, D4, D3 and D1) | Sequence 3 (D3, D1, D2, P and D4) | Sequence 4 (P, D4, D1, D2 and D3) | Sequence 5 (D1, D3, P, D4 and D2) |
|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 11 |
| Completed | 10 | 11 | 12 | 12 | 9 |
| Not completed | 2 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 2 |
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
| minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Placebo |
|---|---|---|---|---|---|
| Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 | -18.9 ± 4.44 | -32.0 ± 4.50 | -45.1 ± 4.47 | -61.4 ± 4.44 | -13.6 ± 4.50 |
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
| Minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Placebo |
|---|---|---|---|---|---|
| Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2 | -37.92 ± 48.76 | -44.61 ± 41.28 | -44.81 ± 41.56 | -44.88 ± 44.22 | -33.88 ± 41.74 |
Collected over Start of screening until the end of the safety follow-up period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-blind Placebo (Run-in Period) | 0/58 (0%) | 0/58 (0%) | 7/58 (12.1%) |
| Placebo | 0/54 (0%) | 0/54 (0%) | 11/54 (20.4%) |
| ACT-541468 5 mg | 0/56 (0%) | 0/56 (0%) | 14/56 (25%) |
| ACT-541468 10 mg | 0/54 (0%) | 0/54 (0%) | 12/54 (22.2%) |
| ACT-541468 25 mg | 0/55 (0%) | 0/55 (0%) | 10/55 (18.2%) |
| ACT-541468 50 mg | 0/56 (0%) | 0/56 (0%) | 16/56 (28.6%) |
| Event | Single-blind Placebo (Run-in Period) | Placebo | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/58 | 2/54 | 0/56 | 1/54 | 0/55 | 4/56 |
| Back painMusculoskeletal and connective tissue disorders | 0/58 | 2/54 | 0/56 | 0/54 | 1/55 | 0/56 |
| Gait disturbanceGeneral disorders | 1/58 | 0/54 | 2/56 | 1/54 | 1/55 | 1/56 |
| NasopharyngitisInfections and infestations | 0/58 | 1/54 | 1/56 | 1/54 | 0/55 | 2/56 |
| DizzinessNervous system disorders | 0/58 | 0/54 | 2/56 | 1/54 | 0/55 | 0/56 |
| HeadacheNervous system disorders | 2/58 | 1/54 | 2/56 | 0/54 | 1/55 | 1/56 |
| Bundle branch block leftCardiac disorders | 0/58 | 1/54 | 0/56 | 0/54 | 0/55 | 0/56 |
| Cerumen impactionEar and labyrinth disorders | 0/58 | 1/54 | 0/56 | 0/54 | 0/55 | 0/56 |
| Abdominal discomfortGastrointestinal disorders | 0/58 | 1/54 | 0/56 | 0/54 | 0/55 | 0/56 |
| Defaecation urgencyGastrointestinal disorders | 0/58 | 0/54 | 1/56 | 1/54 | 1/55 | 0/56 |
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 57 |
| >=65 years | 1 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Median | 69 (65 to 85) |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 39 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 57 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 54 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Insomnia Severity Index(units on a scale) | All Study Participants |
|---|---|
| Mean | 20 (15 to 28) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in May 2017, 6 months.
Results were first posted in Apr 2020, 2 years 10 months after primary completion. A results delay was requested in Apr 2018.
Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →